Screening of Therapeutic Strategies for Huntington's Disease in YAC128 Transgenic Mice
- 16 February 2011
- journal article
- review article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 18 (1) , 77-86
Abstract
SUMMARY: Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an unstable expansion of cytosine‐adenine‐guanine (CAG) repeats in the HD gene. The symptoms include cognitive dysfunction and severe motor impairment with loss of voluntary movement coordination that is later replaced by bradykinesia and rigidity. The neuropathology is characterized by neuronal loss mainly in the striatum and cortex, and the appearance of neuronal intranuclear inclusions of mutant huntingtin. The mechanisms responsible for neurodegeneration are still not fully understood although excitotoxicity and a consequent increase in intracellular calcium concentration as well as the activation of caspases and calapins are known to play a key role. There is currently no satisfactory treatment or cure for this disease. The YAC128 transgenic mice express the full‐length human HD gene with 128 CAG repeats and constitute a unique model for the study of HD as they replicate the slow and biphasic progression of behavioral deficits characteristic of the human condition and show striatal neuronal loss. As such, these transgenic mice have been an invaluable model not only for the elucidation of the neurodegenerative pathways in HD, but also for the screening and development of new therapeutic approaches. Here, I will review the unique characteristics of this transgenic HD model and will provide a summary of the therapies that have been tested in these mice, namely: potentiation of the protective roles of wild‐type huntingtin and mutant huntingtin aggregation, transglutaminase inhibition, inhibition of glutamate‐ and dopamine‐induced toxicity, apoptosis inhibition, use of essential fatty acids, and the novel approach of intrabody gene therapy. The insights obtained from these and future studies will help identify potential candidates for clinical trials and will ultimately contribute to the discovery of a successful treatment for this devastating neurodegenerative disorder.Keywords
This publication has 117 references indexed in Scilit:
- Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expressionHuman Molecular Genetics, 2010
- Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtinNature Medicine, 2009
- EXPRESSION OF CONCERN: Ginsenosides protect striatal neurons in a cellular model of Huntington's diseaseJournal of Neuroscience Research, 2009
- Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's diseaseNeuroscience, 2008
- Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein loadThe Journal of Physiology, 2007
- Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's DiseaseThe Journal of Neuroscience, 2007
- Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s diseaseNeuroscience, 2007
- Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminaseJournal of Clinical Investigation, 2006
- Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal deathNature, 2004
- Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in BrainScience, 1997